The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against ...
The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical study demonstrated NS002 can ach ...
Get the latest on Atea Pharmaceuticals’ Q3 2025 earnings, HCV Phase III progress, hepatitis E pipeline expansion, and key financial updates.
If you haven’t done so already, we encourage you to determine your short- and long-term career goals to identify your postdoc training needs. Creating an IDP is a great way to do this, and when you’re ...
Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study in ...
SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing ...
Facility completion marks a major milestone as equipment procurement and installation begin; exploration planning accelerates ...
Homerun Resources Inc. (TSXV: HMR) (OTCQB: HMRFF) (“Homerun” or the “Company”) is pleased to announce that the Company has ...
Hello, and thank you for joining us for i-80 Gold's 2025 Third Quarter Conference Call and Webcast. Today's company presenters include Richard Young, President and Chief Executive Officer of i-80 Gold ...
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical ...
PRNewswire/ - i-80 GOLD CORP. (TSX: IAU) (NYSE American: IAUX) ("i-80 Gold" or the "Company") reports its operating and financial results for the three and nine months ended September 30, 2025, ...
Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas BioP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback